Combination regimen of leflunomide plus methylprednisolone in a female patient with reactive arthritis and concomitant IgA nephropathy

Chinese Medical Journal

Volumn 123, Issue 3, 2010, Pages 375-378

  Chen, Yi Zhi ^a   Zhao, Xue Zhi ^a   Wu, Jun ^a   Mei, Chang Lin ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Arthritis, reactive; Female; Glomerulonephritis, IgA; Leflunomide; Methylprednisolone

Indexed keywords

AUTOANTIBODY; CELECOXIB; HLA B27 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; LEFLUNOMIDE; METHYLPREDNISOLONE; RHEUMATOID FACTOR;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CASE REPORT; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DYSURIA; EXERCISE; FAMILY HISTORY; FEMALE; FEVER; HEMATURIA; HOSPITAL MANAGEMENT; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KLEBSIELLA; MUSCULOSKELETAL PAIN; NEPHRITIS; NIGHT SWEAT; ODYNURIA; PATELLA TENDON; REACTIVE ARTHRITIS; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY; SYNOVITIS; TIBIA TUBEROSITY; URINARY TRACT INFECTION; WEIGHT REDUCTION;

ADOLESCENT; ADULT; ARTHRITIS, REACTIVE; DRUG COMBINATIONS; FEMALE; GLOMERULONEPHRITIS, IGA; HUMANS; ISOXAZOLES; MALE; METHYLPREDNISOLONE; YOUNG ADULT;

EID: 76649086045     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2010.03.023     Document Type: Article

References (23)

1. Chou CT. Factors affecting the pathogenesis of ankylosing spondylitis. Chin Med J 2001; 114: 211-212.
2. Jacques P, Mielants H, De Vos M, Elewaut D. Spondyloarthropathies: progress and challenges. Best Pract Res Clin Rheumatol 2008; 22: 325-337.
3. Kanterewicz E, Sanmarti R, Collado A, Brancos MA, Torras A, Rotes Querol J. IgA nephropathy in a young female with ankylosing spondylitis. Br J Rheumatol 1987; 26: 396-397.
4. Lai KN, Li PK, Hawkins B, Lai FM. IgA nephropathy associated with ankylosing spondylitis: occurrence in women as well as in men. Ann Rheum Dis 1989; 48: 435-437.
5. Matsuda M, Suzuki A, Miyagawa H, Shimizu S, Ikeda S. Coexistence of IgA nephropathy and undifferentiated spondyloarthropathy in a female patient. Clin Rheumatol 2006; 25: 415-418.
6. Wasilewska A, Zoch-Zwierz WM, Tenderenda E, Szynaka B. IgA nephropathy in a girl with psoriasis and seronegative arthritis. Pediatr Dermatol 2008; 25: 408-409.
7. Jennette JC, Ferguson AL, Moore MA, Freeman DG. IgA nephropathy associated with seronegative spondyl-arthropathies. Arthritis Rheum 1982; 25: 144-149.
8. Dard S, Kenouch S, Méry JP, Baumelou A, Beaufils H, Baglin A. A new association: Ankylosing spondylitis (AS) and Berger disease (BD) [abstract]. Kidney Int 1983; 24: 129.
9. Bruneau C, Villiaumey J, Avouac B, Martigny J, Laurent J, Pichot A, et al. Seronegative spondyloarthropathies and IgA glomerulonephritis: a report of four cases and a review of the literature. Semin Arthritis Rheum 1986; 15: 179-184.
10. Inglis FG, Henderson I, Sanders S, Kerr M. Reiter's disease, keratoderma blennorrhagica and rapidly progressive (crescentic) IgA glomerulonephritis. Nephrol Dial Transplant 1994; 9: 824-826.
11. Satko SG, Iskandar SS, Appel RG. IgA nephropathy and Reiter's syndrome. Report of two cases and review of the literature. Nephron 2000; 84: 177-182.
12. Sakellariou GT, Vounotrypidis P, Berberidis C. Infliximab treatment in two patients with psoriatic arthritis and secondary IgA nephropathy. Clin Rheumatol 2007; 26: 1132-1133.
13. Breedveld FC, Dayer JM. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 2000; 59: 841-849.
14. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999; 353: 259-266.
15. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999; 159: 2542-2550.
16. Bao C, Chen S, Gu Y, Lao Z, Ni L, Yu Q, et al. Leflunomide, a new disease-modifying drug for treating active rheumatoid arthritis in methotrexate-controlled phase II clinical trial. Chin Med J 2003; 116: 1228-1234.
17. Haibel H, Rudwaleit M, Braun J, Sieper J. Six months open label trial of leflunomide in active ankylosing spondylitis. Ann Rheum Dis 2005; 64: 124-126.
18. Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004; 50: 1939-1950.
19. Nash P, Thaci D, Behrens F, Falk F, Kaltwasser JP. Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study. Dermatology 2006; 212: 238-249.
20. Ravindran V, Scott DL, Choy EH. A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. Ann Rheum Dis 2008; 67: 855-859.
21. Xu X, Williams JW, Bremer EG, Finnegan A, Chong AS. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J Biol Chem 1995; 270: 12398-12403.
22. Lou T, Wang C, Chen Z, Shi C, Tang H, Liu X, et al. Randomised controlled trial of leflunomide in the treatment of immunoglobulin A nephropathy. Nephrology (Carlton) 2006; 11: 113-116.
23. Thielen AM, Barde C, Janer V, Borradori L, Saurat JH. Reiter syndrome triggered by adalimumab (Humira) and leflunomide (Arava) in a patient with ankylosing spondylarthropathy and Crohn disease. Br J Dermatol 2007; 156: 188-189.